In six months, ABL Diagnostics has already achieved 77.9% of 2025 annual sales and 29.7% higher than the net profit recorded for the full 2025 financial year
-- Revenue of EUR5.415 million in H1 2026, compared to EUR2.849 million in
H1 2025, representing a reported growth of 90.0%
-- EBITDA of EUR1.315 million in H1 2026, compared to EUR0.295 million in
H1 2025, with an EBITDA margin increased to 24.3%, compared to 10.3% a
year earlier
-- Operating income, or EBIT, of EUR1.115 million in H1 2026, compared to
an operating loss of EUR0.066 million in H1 2025
-- Net income of EUR1.280 million in H1 2026, compared to EUR0.289 million
in H1 2025, and already 29.7% higher than the EUR0.987 million recorded
for the full year 2025
-- H1 2026 revenue representing 44.2% of the 2026 full-year guidance of
EUR12.265 million published on June 1, 2026
WOIPPY, France--(BUSINESS WIRE)--September 08, 2026--
Regulatory News:
ABL Diagnostics (Euronext Paris: ABLD -- ISIN: FR001400AHX6) (the "Company"), a company specializing in molecular diagnostic solutions, healthcare software and clinical research services, today reported its results for the first half ended June 30, 2026.
The Board of Directors of ABL Diagnostics, meeting on September 8, 2026, approved the Company's half-year financial statements as of June 30, 2026. These financial statements are subject to a limited review by the statutory auditor, whose work is still in progress.
The first half of 2026 confirms the acceleration of ABL Diagnostics' change of scale. Sustained revenue growth is accompanied by a significant improvement in operating profitability and net income.
This performance reflects the growth of the Company's historical activities, the ramp-up of the UltraGene range (formerly Fast Track Diagnostics), the development of software activities and the growing contribution of distribution and services activities, which have been integrated into the portfolio since 2025.
KEY FINANCIAL INDICATORS
In thousands of euros H1 2026 H1 2025 Reported change -------------------------- ------- -------- ------------------ Turnover 5 415 2 849 +2,566, or +90.0% -------------------------- ------- -------- ------------------ EBITDA 1 315 295 +1,020, or +346.5% -------------------------- ------- -------- ------------------ EBITDA margin 24,3 % 10,34 % +14.0 points -------------------------- ------- -------- ------------------ Operating income, or EBIT 1 115 (66) +1 181 -------------------------- ------- -------- ------------------ EBIT margin 20,6 % (2,31) % +22.9 points -------------------------- ------- -------- ------------------ Current income before tax 1 086 (27) +1 113 -------------------------- ------- -------- ------------------ Income net of income tax 194 316 -122, or -38.6% -------------------------- ------- -------- ------------------ Net income 1 280 289 +991, or +343.4% -------------------------- ------- -------- ------------------ Free cash 853 912 -59, or -6.4% -------------------------- ------- -------- ------------------
ACTIVITY
Reported growth of 90.0% in the first half of 2026
ABL Diagnostics' revenue reached EUR5.415 million in the first half of 2026, compared to EUR2.849 million in the first half of 2025, an increase of EUR2.566 million and a reported growth of 90.0% compared to the same period last year.
The growth recorded during the first half reflects the combined contribution of:
-- historical genotyping activities by sequencing;
-- DeepChek(R), ViroScore(R), MicrobioChek(R), and NADIS(R) software
solutions;
-- the ramp-up of the UltraGene range (formerly Fast Track Diagnostics);
-- the distribution of Vela Diagnostics solutions;
-- products and services distributed on behalf of CDL Pharma;
-- the deployment of the international trade network.
The 2025 financial year was marked by the gradual start of several growth drivers. The Yearly Financial Statements 2025 mentioned the first contributions of UltraGene, Vela Diagnostics and the distribution of CDL Pharma's activities.
COMPARISON WITH FISCAL YEAR 2025
This comparison compares the results of the first half of 2026, covering a period of six months, with the results of the 2025 financial year, covering a period of twelve months. It is presented to situate the level of performance achieved as of June 30, 2026, and does not constitute an extrapolation of the expected performance for the full year 2026.
In thousands of
euros H1 2026 FY 2025 released Variance H1 2026 level
-------------------- ------- ---------------- -------- -------------------
Turnover 5 415 6 950 -1 535 77.9% of FY 2025
-------------------- ------- ---------------- -------- -------------------
Operating income, or
EBIT 1 115 290 +825 384.5% of FY 2025
-------------------- ------- ---------------- -------- -------------------
Net income 1 280 987 +293 129.7% of FY 2025
-------------------- ------- ---------------- -------- -------------------
-35.2% of the level
at 31 December
Free cash 853 1 316 -463 2025
-------------------- ------- ---------------- -------- -------------------
The data published for the 2025 financial year showed revenue of EUR6.950 million, operating income of EUR0.290 million, net income of EUR0.987 million, cash flow from operations of EUR1.383 million, available cash of EUR1.316 million and net debt of EUR0.933 million.
Thus, in six months, ABL Diagnostics has carried out:
-- 77.9% of revenue recorded for the twelve months of fiscal 2025;
-- operating income representing 384.5% of operating income for the 2025
financial year;
-- Net income representing 129.7% of 2025 annual net income, 29.7% higher
than the previous year.
RESULTS
EBITDA of EUR1.315 million and EBITDA margin of 24.3%
EBITDA for the first half of 2026 was EUR1.315 million, compared to EUR0.295 million in the first half of 2025, an increase of EUR1.020 million and an increase of 346.5% compared to the same period of the previous year.
The EBITDA margin was 24.3% of revenue in the first half of 2026, compared to 10.34% in the first half of 2025, an improvement of 14.0 points.
This evolution reflects in particular:
-- the increase in the level of activity; -- better absorption of fixed costs; -- the evolution of the business mix; -- the growing contribution of new ranges and services; -- control of operating costs.
EBITDA reconciliation
In thousands of euros H1 2026 H1 2025
---------------------------------- ------- -------
Operating income, or EBIT 1 115 (66)
---------------------------------- ------- -------
Net depreciation and amortization 189 363
---------------------------------- ------- -------
Net impairment charges 12 0
---------------------------------- ------- -------
Trade-ins and other adjustments (1) (3)
---------------------------------- ------- -------
EBITDA 1 315 295
---------------------------------- ------- -------
No differences resulting from rounding are significant.
EBIT of EUR1.115 million
Operating income, or EBIT, reached EUR1.115 million in the first half of 2026, compared to an operating loss of EUR0.066 million in the first half of 2025, an absolute improvement of EUR1.181 million. The EBIT margin reached 20.6% in the first half of 2026, compared to -2.31% in the first half of 2025, an improvement of 22.9 points. By way of comparison, operating income for the full year 2025 was EUR0.290 million, representing an operating margin of 4.2%.
Financial income and current income before tax
Financial income was -EUR29k in the first half of 2026, compared to +EUR39k in the first half of 2025, a decrease of EUR68k. Current income before tax reached EUR1.086 million in the first half of 2026, compared to a current loss before tax of EUR0.027 million in the first half of 2025, an absolute improvement of EUR1.113 million.
Net income of EUR1.280 million
Net income reached EUR1.280 million in the first half of 2026, compared with EUR0.289 million in the first half of 2025, an increase of EUR0.991 million and an increase of 343.4%. The net margin reached 23.6% in the first half of 2026, compared with 10.1% in the first half of 2025, an improvement of 13.5 points. Net income for the first half of 2026 was also EUR293k, or 29.7%, higher than the net income of EUR987k recorded for the full year 2025.
RESEARCH, DEVELOPMENT AND TAXATION
EUR1.150 million in eligible expenditure and EUR345k in CIR/CII
In the first half of 2026, research and development expenses eligible for the Research Tax Credit $(CIR)$ and the Innovation Tax Credit $(CII)$ are estimated at EUR1.150 million. These expenses led to the recognition of an estimated CIR/CII of EUR345k for the first half of 2026.
These investments include:
-- molecular diagnostics; -- syndromic PCR panels; -- genotyping solutions by sequencing; -- analysis and interpretation software; -- regulatory and industry work associated with product development.
Key tax elements
In thousands of euros H1 2026 H1 2025 Variation
---------------------------------- ------- ------- ---------------
Expenses eligible for the CIR/CII 1 150 1 037 113
---------------------------------- ------- ------- ---------------
CIR/CII generated over the period 345 311 34
---------------------------------- ------- ------- ---------------
Income net of income tax 194 316 -122, or -38.6%
---------------------------------- ------- ------- ---------------
Operating taxes 12 21 -9, or -42.9%
---------------------------------- ------- ------- ---------------
The "income taxes" item shows net accounting income of EUR194k in the first half of 2026, compared to net income of EUR316k in the first half of 2025, a decrease of EUR122k and 38.6%.
A distinction should be made between:
-- the CIR/CII generated for the half-year, estimated at EUR345k;
-- net income recognized in the income statement, of EUR194k;
-- the tax receivable recorded on the balance sheet, of EUR852k as of June
30, 2026.
These amounts correspond to different accounting and tax concepts and should not be added together.
Taxes and similar payments recorded as operating expenses amounted to EUR12k in the first half of 2026, compared with EUR21k in the first half of 2025, a decrease of EUR9k and 42.9%.
FINANCIAL POSITION AND CASH POSITION
Available cash stood at EUR853k on June 30, 2026, compared to EUR1.316m on December 31, 2025, a decrease of EUR463k and 35.2%.
This development must be assessed in the light of:
-- movements in working capital requirements; -- investments made during the first half of the year; -- the collection schedule for customer and tax receivables; -- of the financing movements that occurred during the period.
It is important to note that the Company transferred EUR255k, composed of EUR165k for intangible assets and EUR60k for tangible assets, and the acquisition of stocks for a lump sum of EUR30k, from its equity to support the offer presented to the Commercial Court of Evry for the takeover of the assets and activities of Texcell France supported at the hearing on June 29, 2026.
In thousands of euros June 30, 2026 December 31, 2025 Variation --------------------------- ------------- ----------------- --------------- Free cash 686 1 316 -630, or -47.9% --------------------------- ------------- ----------------- --------------- Profit tax claim 852 658 +194, or +29.5% --------------------------- ------------- ----------------- --------------- VAT receivable 189 242 -53, or -21.9% --------------------------- ------------- ----------------- --------------- Tax and social security debts 388 349 +39, or +11.2% --------------------------- ------------- ----------------- --------------- Own shares 168 234 -66, or -28.21% --------------------------- ------------- ----------------- --------------- Shareholders' equity 7 101 7 633 -532, or -6.97% --------------------------- ------------- ----------------- ---------------
PROGRESS REPORT ON THE 2026 ROADMAP
On June 1, 2026, ABL Diagnostics published a roadmap targeting annual revenue of EUR12.265 million in 2026, compared to EUR6.950 million in 2025, i.e. a targeted annual growth of 76.5%.
Completed as of June 30, 2026 and completion rate
Balance to
In thousands Achieved FY FY 2026 Completed be realized
of euros 2025 Target H1 2026 Completion in H2
------------ ------------ ------------ ----------- ---------- -----------
Turnover 6 950 12 265 5 415 44,2 % 6 850
------------ ------------ ------------ ----------- ---------- -----------
Revenue for the first half of 2026 represented:
-- 44.2% of the 2026 annual target; -- 77.9% of revenue for the full year 2025.
This comparison is purely arithmetic. The roadmap published on June 1, 2026, covers the full year and does not set a half-year target. It provides for a ramp-up of the UltraGene, Vela Diagnostics and CDL Pharma activities over the full year.
The 2026 roadmap includes annual targets of EUR1.582 million for UltraGene, EUR3.906 million for the HIV business, EUR1.565 million for Vela Diagnostics and EUR2.482 million for CDL Pharma.
STATEMENT BY CHALOM SAYADA, MANAGING DIRECTOR
"The first half of 2026 marks a significant acceleration in ABL Diagnostics' trajectory. Our revenue reached EUR5.42 million, up 90.0% compared to the first half of 2025. This increase is accompanied by a substantial improvement in profitability, with an EBITDA of EUR1.32 million, an EBITDA margin of 24.3% and an operating profit of EUR1.12 million.
In six months, we generated 77.9% of revenue for the full year 2025 and our net income of EUR1.28 million is 29.7% higher than for the twelve months of the previous year. These results reflect the ramp-up of our historical activities and our new growth drivers, as well as ABL Diagnostics' ability to convert the growth of its business into results.
As of June 30, 2026, the Company achieved 44.2% of its full-year revenue target. We continue to execute our roadmap with discipline, while remaining attentive to the timing of orders and deliveries, regulatory conditions and the operational ramp-up of the activities integrated into our portfolio. >>
2026 OUTLOOK
Considering the results recorded for the first half of 2026 and the information available at the date of this press release, ABL Diagnostics maintains its revenue target of EUR12.265 million for the 2026 financial year at this stage.
The achievement of this objective remains dependent on:
-- the timing of orders and deliveries; -- the ramp-up of the UltraGene range; -- the development of HIV activities; -- the contribution of Vela Diagnostics and CDL Pharma; -- supply conditions; -- regulatory deadlines; -- the collection of customer receivables; -- of the general evolution of the markets in which the Company operates.
In addition, since July 21, 2026, ABL Diagnostics has integrated the assets of Texcell France acquired at the helm of the Evry Commercial Court as part of a receivership procedure. 29 new employees have been integrated into ABL Diagnostics as part of this operation.
The Company will update its revenue target of EUR12.265 million for the 2026 financial year by integrating the revenues and costs associated with the ex-assets of Texcell France.
About ABL Diagnostics $(ABLD)$
ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:
-- Molecular polymerase chain reaction $(PCR)$ detection -- UltraGene, and -- Genotyping by DNA sequencing -- DeepChek(R).
ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.
Following the acquisition of TEXCELL's operations, ABL Diagnostics is expanding its activities in the life sciences sector by integrating expertise and services dedicated to virology, biosafety testing and biopharmaceutical development support.
ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.
An expanding portfolio of microbiology products:
-- HIV -- Drug resistance testing, including a whole genome kit.
-- SARS-CoV-2, Tuberculosis, Hepatitis B and C -- Advanced Detection
Solutions.
-- Microbiome and taxonomy -- 16s/18s RNA-based analyses.
-- Other viral and bacterial targets -- Comprehensive molecular assays.
Integrated Solutions
-- Real-time syndromic PCR tests
-- Nadis(R) -- Patient Medical Record used in more than 200 hospitals in
France for the management of HIV and hepatitis.
ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD -- ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260908089476/en/
CONTACT: ABL Diagnostics SA
Société anonyme au capital de 1 611 465,60 euros
Headquarters : 72C route de Thionville - 57140 WOIPPY
552 064 933 R.C.S. METZ
Tel : +33 (0)7 83 64 68 50
Email : info@abldiagnostics.com
https://www.abldiagnostics.com/